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Chimeric antigen receptor (CAR) T cell therapy is an emerging form of immunotherapy that has 
revolutionised the treatment of some cancers. This is especially true for relapsed and refractory 
(r/r) lymphoma where it has provided previously terminal patients with a new, potentially 
curative, treatment option. While the therapeutic outcomes for CAR T cells have been impressive, 
the quality control during therapy manufacture remains an area in which a lot of progress is 
required. There is currently no reagent capable of directly detecting the expression of CAR on the 
surface of transduced T cells. This leads to a large degree of potential variability between CAR T 
cell preparations that cannot be quantified. 
This research aimed to address this problem through the generation of an anti-idiotypic antibody 
capable of recognising the FMC63 derived CAR utilised for anti-CD19 CAR T cell therapy. This 
was done via the immunisation of mice with FMC63 scFv containing antigen and generation of 
hybridomas. Hybridomas were screened against FMC63 scFv via ELISA to determine those that 
were secreting scFv specific monoclonal antibodies (mAb). Clones secreting mAb identified as 
scFv specific were then screened against cell surface expressed anti-CD19 CAR via flow 
cytometry. None of the mAb that were seen to be specific for FMC63 scFv via ELISA were able 
to detect CAR expression on the surface of cells. Isotype analysis of FMC63 scFv specific mAb 
indicated a lack of T cell help, and thus a lack of many of the typical process mAb undergo to 
become high-affinity and antigen specific. As such, an alternative technique in which additional 
T cell epitopes were introduced to the antigen was developed. 
These results identify that immunisation of mice with a weak FMC63 scFv containing antigen is 
not sufficient for the production of a high-affinity anti-idiotypic mAb for detection of FMC63 
derived CAR.  
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Cancer is a disease that develops following the loss of a cell’s normal proliferative program and 
is often associated with the ability of malignant cells to metastasise to other areas of the body. 
Homeostatic cellular proliferation is subject to strict regulation in the form of environmental or 
cell intrinsic cues that control cell cycle progression.1, 2 Mutations in the coding or regulatory 
regions of genes can lead to a loss of cell cycle control, allowing for the uncontrolled proliferation 
typical of cancerous cells.1 Alternatively, cancers may arise following oncogenic transformation 
of cells by viruses such as human papillomavirus, hepatitis B and hepatitis C virus and Epstein–
Barr virus. Tumour cells are capable of dividing independent of environmental signals, effectively 
gaining autonomy over cellular division.2 Additionally, specific mutations such as in the p53 gene, 
can lead to these cells becoming resistant to apoptosis and thus harder to be removed from the 
body.3 The result of these mutations is the development of a cell population that is able to resist 
elimination and possess abnormal proliferative properties.4 
Cancer can present in many different ways, with over 100 distinct forms.1 One of the most 
common blood cancers is lymphoma, accounting for roughly 4% of cancers diagnosed worldwide 
each year.5 The disease has a high incidence in young people, in which the more aggressive forms 
are also more common.5, 6 Lymphoma affects the cells of the immune system known  
as lymphocytes, namely B and T cells, and encompasses a variety of distinct cancers.7 The 
majority of lymphomas affect cells of B cell origin.7 There are two broad classes of lymphoma; 
Hodgkin (HL) and non-Hodgkin (NHL), which differ in their tumour morphology and  
incidence.7, 8  
Acute lymphoblastic leukemia (ALL) is a form of cancer that results from malignant 
transformation of lymphoid progenitor cells in areas such as the bone marrow.9 The majority  
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of ALL cases involve transformation of cells of B cell origin, accounting for 75% of the  
disease (B-ALL).9 The global incidence of ALL is lower than for lymphoma, however, the disease 
shares similar propensity to affect pediatric patients.5, 9  
1.2 Treatment of B cell malignancies 
Despite the high incidence of lymphoma globally, the treatment options available are effective in 
most cases. In some forms of NHL, where patients have favourable disease characteristics, the 
disease is treated with observation only, with invasive treatment only administered as required.10 
Individuals deemed to have more serious disease are typically treated with a combination of 
chemotherapy and radiotherapy. These combination therapy regimens have improved drastically 
in recent times, now achieving complete response rates as high as 70%.8, 11 This therapy was 
revolutionised by the addition of Rituximab, a monoclonal antibody (mAb) against the cluster of 
differentiation 20 (CD20) surface protein, to the other established chemotherapeutic agents.7, 11 
Despite high response rates, there remains a subset of patients where this therapy is not effective, 
as high as 30-40% in some lymphomas.12 These individuals suffer from either refractory disease, 
which does not respond effectively to therapy, or relapsed disease which returns following an 
initial complete response. Those who suffer from refractory or relapsed (r/r) lymphoma have 
extremely poor prognosis, with the long-term survival typically measured in months rather than 
years.13, 14 
Many new therapies have utilised mAb to specifically target malignant cells.13, 15 These therapies 
aim to augment the host immune system to allow for a robust anti-tumour response capable of 
killing cancerous cells.15 Therapies based upon mAb utilise the specific binding of these 
molecules to a specific antigen, with the selection of an appropriate antigen vital in ensuring a 
treatment is effective. A commonly targeted antigen is CD20 due to restriction to cells of B cell 
lineage, including those that have undergone malignant transfomrtion.16 A number of such 
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therapies have gained Food and Drug Administration (FDA) approval and shown promising 
results in treating r/r B cell malignancies, including lymphoma.13, 17, 18 
Specific mAb binding has also been used to generate chemotherapeutic drugs with  
greater specificity to lymphoma cells. Brentuximab Vedotin (BV) is an antibody-drug  
conjugate consisting of an anti-CD30 mAb conjugated to an apoptotic drug, monomethyl  
auristatin E (MMAE).19 Upon binding to CD30, the mAb-drug conjugate is internalised, MMAE 
is cleaved and released into cells.19, 20 This allows for the specific targeting of the 
chemotherapeutic agent to CD30 expressing cells. This is an attractive option in HL as these 
tumours tend to express high levels of CD30.21 In comparison, non-Hodgkin’s lymphoma tumour 
cells do not tend to express high levels of CD30, however, some evidence indicates that even low 
levels of CD30 expression are sufficient for BV treatment to be effective.22, 23 
1.3 Adoptive cell therapy and CAR T cells 
While mAb based therapies aim to augment the immune system to improve the anti-cancer 
immune response, it is also possible to directly manipulate immune cells to improve anti-cancer 
efficacy. Adoptive cell therapy (ACT) is one such therapy in which T cells are modified to 
improve anti-cancer efficacy.24 T cells provide an attractive option for manipulation due to their 
importance in anti-tumour immune responses. This is evidenced by a high number of tumour 
infiltrating lymphocytes (TIL) being correlated with improved outcomes in a number of major 
solid cancers.25, 26 Additionally, it has been shown that mice with T cell deficiencies were more 
prone to the development of tumours.4, 27 Therapies based upon TIL have been explored, with  
ex vivo expansion of tumour specific T cells to allow for the immune-modulatory environment of 
solid cancers to be overcome.28 Such therapies have been shown to induce complete responses in 
up to 40% of melanoma patients, but have not been widely applicable to other cancers.24, 29 This 
is likely due to the high mutational load of melanoma producing more immunogenic T cell 
epitopes, as compared to other tumours.30 
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Chimeric antigen receptor (CAR) T cell therapy is an alternative form of ACT that re-routes the 
activation of a patient’s T cells to elicit a specific anti-tumour response. T cells are removed from 
a patient via apheresis and then transfected with a viral vector capable of introducing a CAR 
transgene into the host cell genome.14 The integrated transgene then expresses an artificial 
receptor that allows for T cells to be directly targeted to a pre-determined antigen on the surface 
of tumour cells, becoming activated upon antigen recognition.31, 32 This new activation modality 
allows for CAR expressing T cells to avoid some of the typical methods of immune-escape by 
tumours, such as sub-optimal MHC-peptide loading or lack of co-stimulatory signals.32, 33 The 
introduction of a CAR to the surface of T cells expands the scope of ACT, allowing for targeting 
of tumours based on the expression of a predetermined surface antigen.24 
The structure of CAR can vary between constructs but all tend to maintain three common features: 
an antigen recognition domain derived from an antigen-specific mAb, a cell-membrane anchoring 
transmembrane domain and an intracellular activation domain (Figure 1).33-35 The first description 
of a CAR was a two-chain construct that fused the variable and light chains of an anti-
trinitrophenol mAb variable domain to the alpha and beta T cell receptor (TCR) chains.36 Most 
current CAR constructs, including those that are FDA licensed and used in clinical trials, are a 
single fusion peptide capable of both antigen recognition and activation of T cells.34, 37 
The extracellular antigen recognition domain provides CAR T cells with the ability to bind tumour 
associated antigen (TAA) in a manner analogous to antibody.34 This extracellular recognition 
domain typically consists of a single chain variable fragment (scFv), consisting of the variable 
light (VL) and variable heavy (VH) regions of the parent antibody (Figure 1). This allows for CAR 
constructs to possess the determinants required for antigen recognition whilst minimising the size 
of the CAR transgene.38, 39 Many different antigens have been targeted with CAR  
T cell therapy with varying results.40 By far the most successful form of CAR T cell therapy has 
been anti-CD19 CAR T cell therapy for r/r lymphoma. These CAR constructs contain a CD19 
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specific scFv derived from the mAb FMC63, with such a construct present in both currently  
FDA-approved CAR T cell therapies.41 The antigen recognition domain is typically anchored to 
the cell through a flexible hinge and transmembrane domain (Figure 1).31 These aspects of the 
CAR structure aim to provide the scFv with flexibility to bind antigen and give the CAR stability 
in the cellular membrane respectively.34 
The intracellular activation domain of a CAR construct is the area that has undergone the most 
change during CAR T cell therapy development.42 The initial constructs, termed ‘first generation’, 
possessed only a CD3-ζ signalling domain, sufficient for activation of cells and induction of 
cytotoxic effects in vitro (Figure 1).36 However, these cells were prone to exhaustion and were 
unable to induce meaningful anti-tumour effects in clinical trials.43, 44  
Physiological T cell activation requires a multitude of co-stimulatory signals, in addition to TCR 
signalling, to allow for effective T cell activation and function.43 In an effort to mimic this in CAR 
constructs, intracellular regions of common co-stimulatory domains have been incorporated into 
the intracellular domain in subsequent CAR generations (Figure 1).43 The most commonly 
incorporated co-stimulatory domains are CD28 or CD137 (4-1BB).43 The expression of 4-1BB is 
upregulated on T cells following activation and has been shown to improve cellular differentiation 
and cytokine production.45 T cells express CD28 on their surface and the protein competes with 
CD80 for the binding of CD86 on antigen presenting cells.46 The addition of these co-stimulatory 





Figure 1. Generations of CAR constructs used for CAR T cell therapy. 
All CAR constructs contain an extracellular scFv and hinge domain anchored to the cell 
membrane by a transmembrane domain (TM). First generation CAR constructs contain only a 
CD3-ζ signaling domain (CD3, light blue). Second generation CAR also have either CD28 (CD28, 
pink) or 4-1BB (4-1BB, purple) co-stimulatory domains in addition to CD3-ζ. Third generation 
CAR contain both co-stimulatory domains and a CD3-ζ signaling domain.  
Original figure  
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Activated T cell receive a multitude of co-stimulatory signals, each of which has a unique role in 
T cell function. Chimeric antigen receptor T cell therapy is no different, with the incorporation of 
different co-stimulatory domains having varying effects on CAR T cell function.34, 48 
Incorporation of CD28 into CAR constructs leads to stronger, more rapid signalling resulting in 
impressive improvements in effector function and cell proliferation.48, 49 Alternatively, 4-1BB 
containing CAR constructs lead to a comparatively slower expansion than those with CD28 co-
stimulatory domains, but show improved persistence.47, 48 Third generation CAR constructs 
incorporate two costimulatory domains (usually CD28 with 4-1BB) and have improved expansion 
and persistence when compared to second generation constructs (Figure 1).50 
1.4 Manufacture of CAR T cells and assessment of variability  
In order to generate CAR T cells, it is necessary to stably and reliably deliver the CAR encoding 
gene to T cells. This is typically achieved through the use of a lentiviral vector (LV), a replication 
deficient viral vector derived from the human immunodeficiency virus 1 (HIV-1).51 The use of 
LV vectors has a number of benefits compared to other viral vectors, including the ability to stably 
integrate a gene into host cell genomes, as well as transduction of non-replicating cells.52, 53 In 
order to generate these viral vectors, the current practice is to transfect a multiple plasmid 
construct into a packaging cell line in which assembly of the virus can take place.53, 54 The multiple 
plasmid system typically consists of four plasmids encoding: (i) the vector genome and gene of 
interest, (ii) reverse transcription machinery/structural proteins, (iii) envelope glycoprotein and 
(iv) ribonucleic acid (RNA) encapsulation elements.55 The use of a multiple plasmid system 
greatly improves the safety of LV vectors when compared to the original single-genome systems, 
but is less than ideal for reducing variability during CAR T cell manufacture.55 
Current manufacture techniques for CAR T cells are sufficient for laboratory use, however, a 
major concern for clinical use is the potential variability between separate CAR T cell 
preparations. Variability can emerge from both the manufacture of LV vector as well as the 
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transduction of T cells with the viral vector. Lentiviral vector manufacture can be a variable 
process, with problems related to residual plasmid deoxyribose nucleic acid (DNA) contamination 
as a result of the multiple plasmid transfection system.54, 56 Attempts to avoid this multiple plasmid 
transfection variability have involved the generation of a stable cell line encoding the core aspects 
of lentiviral vectors.57, 58 This has been readily achieved with other viral vectors, however, the 
toxicity of some key lentiviral elements have hampered this process.58-60 
Additionally, the transfection of T cells with a LV vector encoding a CAR gene and the transition 
to a surface expressed CAR protein is a far from perfect process.54 It has been shown that the vast 
majority of lentiviral RNA genomes that enter host cells and are converted to DNA do not 
integrate in the host cell genome.54, 61 This is a factor that has been partially alleviated through the 
addition of a central polypurine tract to lentiviral constructs that minimises attack by enzymes that 
can lead to abortive lentiviral transfection.51, 62, 63 Studies with a green fluorescent protein (GFP) 
reporter gene have also shown that not all of the LV encoded genes that are introduced in to host 
cell genomes produce a functional protein.64 Methods in which LV genome integration was used 
to measure transduction efficiency were shown to overestimate functional protein expression by 
as much as 60-fold.64 
This potential variability introduces the possibility that surface CAR expression, the most 
important determinant of CAR T cell anti-cancer efficacy, can also vary between separate 
preparations. As well as dictating anti-cancer efficacy, CAR expression in patient blood is also 
commonly used as a measure of persistence, considered a surrogate measure of treatment 
success.65 There is currently no readily available way to directly measure the expression of CAR 
on the surface of T cells following transduction. CAR constructs used for in vitro research have 
incorporated a marker in the extracellular portion of the CAR.66 These tags are not present in the 
clinically relevant CAR constructs due to concerns related to potential immunogenicity.67 The use 
of these extracellular tags allows for detection of surface expressed CAR via flow cytometry 
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following targeting with a fluorescently conjugated antibody. Alternatively, the same principle 
has been applied with targeting the hinge region of CAR constructs that are derived from IgG1 or 
IgG4.66 The currently FDA approved CAR constructs lack either of these aspects and thus these 
techniques are not applicable.67, 68 
The ideal agent for CAR detection recognises the scFv of a specific CAR construct since this is 
both surface expressed and present on all CARs of a given specificity. Such a reagent has been 
described previously with an anti-idiotypic antibody (clone 136.20.1) generated capable of 
recognising the FMC63 scFv used in a number of anti-CD19 CAR constructs.66 The 136.20.1 
reagent was utilised in a number of the seminal anti-CD19 CAR T cell trials, but is no longer 
readily available outside of the MD-Anderson Cancer Center due to intellectual property and 
commercial constraints.69, 70 The development of another such agent would address a major 
problem in the ability of researchers and clinicians alike to effectively measure the surface 
expression of all CAR constructs that lack the mentioned elements, including those that are 
licensed for clinical use. 
1.5 Anti-Idiotype Antibodies 
The typical function of antibodies is to recognise foreign invaders and initiate an immune response 
capable of eliminating potential invaders.71 This process requires antibodies to possess a vast array 
of different antigen binding capabilities. To allow for this, antibodies undergo both genetic and 
antigen-dependent maturation to ensure high affinity interactions with their potential antigens.72 
The variability in the VH and VL domains is important for correct functioning of the humoral arm 
of the immune system. However, this also introduces a number of unique regions into the antibody 
structure that have potential to themselves be recognised as antigens.73 These unique regions are 
known as idiotopes, with the idiotype of an antibody consisting of all of these determinants 
(Figure 2).74 The idiotype can be recognised by other antibodies, known as anti-idiotypic 
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antibodies. An scFv derived from FMC63, such as those used in anti-CD19 CAR T cells trials, 
possesses the idiotype of the original FMC63 antibody in both the VH and VL.  
1.6 Generation of monoclonal antibodies 
The scope of antibodies for use as therapeutic or diagnostic tools is one of the largest growing 
biotherapeutic fields. For this growth to have been possible it was necessary for a continuous, 
reproducible platform for mAb production to be generated. Such a system was described in 1975 
by Köhler and Milstein through the generation of a hybridoma cell line capable of long-term 
secretion of a single-specificity antibody.75 Hybridomas are formed through the fusion of a plasma 
cell of an immunised animal, typically a mouse or rat, with a myeloma cell, endowing the fused 
cell with the immortality of the myeloma cell and single-clone antibody specificity of the plasma 
cell.76, 77 
The system relies on the fusion of plasma cells with an immortal cell line, with non-fused cells 
lost during the post-fusion screening process. As such, a large number of splenocytes producing 
potentially effective mAb are lost due to unsuccessful fusion. Alternative techniques to identify 
mAb capable of binding a target antigen utilise the display of large scFv libraries from the spleen 
of immunised mice.78, 79 One such technique is phage display, in which an scFv library is 
expressed on the surface of filamentous phage. Multiple bio-panning steps are then utilised to 
identify phage displaying scFv capable of binding to target antigen with high affinity.78 The 
genetic material of the phage is then isolated and the sequence of the antigen specific scFv 
extracted. A study in which mAb were generated against Interleukin receptor 8-β (CXCR2) with 
both hybridoma and phage display technology showed that the mAb from the two techniques 
bound distinct epitopes.80 This indicates that the utilisation of both techniques may maximise the 







Figure 2. Diagrammatic representation of the antigen binding fragment (Fab) of an antibody 
molecule.  
Variable light and heavy chain (VL, VH) and constant light and heavy chain 1 (CL, CH1) regions 
shown. Paratopes are present within the antigen binding domain of an antibody and bind the 
epitope present on a specific antigen. Idiotopes are present in the variable region of an antibody 
and can both be part of and distinct from the antigen binding region. The idiotype contains the 




1.7 Aims and hypothesis 
CAR T cell therapy has proven effective for the treatment of r/r lymphoma but there is a distinct 
lack of appropriate quality control reagents to ensure consistency of the manufactured product. 
There is currently no way to directly assess the surface expression of a CAR following transfection 
of T cells, the single biggest determinant of a CAR T cell therapies anti-tumour efficacy. This 
research aims to: 
1 – Generate appropriate antigens to induce an anti-FMC63 scFv immune response 
2 – Immunise mice with FMC63 scFv antigen  
3 – Generate and screen hybridomas to identify anti-idiotypic mAb that specifically bind 
FMC63 scFv 
4 – Perform functional tests to identify mAb capable of binding to surface expressed anti-
CD19 CAR via flow cytometry 
We hypothesise that the immunisation of mice with FMC63 scFv antigen will generate an immune 
response leading to the identification of an anti-idiotypic mAb capable of detecting the surface 










2.0 Materials and Methods 
 
 Media and solutions 
2.1.1 RPMI-1640 Medium 
1 L: 1× RPMI-1640 Medium sachet (Gibco #31800-022) 
2 g of sodium bicarbonate  
100 U/mL Penicillin (Gibco #15140-122) 
100 µg/mL Streptomycin (Gibco #15140-122)  
55 µM β-mercaptoethanol (BME; Gibco #21985)  
Total volume of 1 L made up using milliQ water  
pH adjusted to 7.3  
0.22 µm filter sterilised  
2.1.2 Dulbecco's Modified Eagle's Medium (DMEM) 
1 L: 1× DMEM sachet (Gibco 12100-046) 
100 U/mL Penicillin 
100 µg/mL Streptomycin 
Total volume of 1 L made up using milliQ water 
pH adjusted to 7.3 
0.22 µm filter sterilised 
2.1.3 Foetal Calf Serum (FCS) / RPMI-1640 Medium 
R5:  95% RPMI-1640 medium 
 5% FCS (Pan Biotech GmbH; Germany) 
R10: 90% RPMI-1640 medium 
 10% FCS 
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2.1.4 Dulbecco’s Phosphate Buffered Saline (PBS) 
1 L:  1× PBS sachet (Gibco #21600-010) 
 Total volume to 1L with milliQ H2O 
 pH adjusted to 7.3 
 0.22 µm filter sterilised 
2.1.5 Luria-Bertani Media (LB)  
1 L: 5g of BactoTM yeast extract 
 10g of BactoTM tryptone, enzymatic digest of casein 
 5g of NaCl 
 Total volume to 1 L with milliQ H2O 
2.1.6 LB Agar 
1 L: 15g of bacteriological agar 
 Total volume to 1 L with LB media 
 Autoclaved and cooled to 65°C 
2.1.7 50× Tris HCl-acetic acid ethylenediaminetetraacetic acid (EDTA) buffer (TAE) 
1 L: 242 g of Tris 
 57 mL of glacial acetic acid 
 100 mL of 0.5 M EDTA, pH 8.0 
 Total volume to 1 L with milliQ H2O 
2.1.8 2× (NH4)2SO4 Buffer 
150 mM Tris-HCl pH 8.8 




2.1.9 2× Taq Polymerase Chain Reaction (PCR) Master Mix 
2× (NH4)2SO4 buffer 
4 mM MgCl2 
0.05 U/µL Taq polymerase 
0.4 mM dNTPs 
Total volume made up with milliQ H2O 
2.1.9 Coomassie Blue G-250 
0.25% Brilliant Blue G-250 
40% methanol 
10% glacial acetic acid 
49.725% milliQ H2O 
2.1.10 Coomassie Blue Destain 
10% glacial acetic acid 
25% methanol 
65% MilliQ H2O 
2.1.11 BOLT MOPS-SDS Running Buffer 
1× BOLT MOPS-SDS (Gibco #NW0412A) 
Total volume made up with MilliQ H2O 
 Restriction enzymes 
Table 1. List of restriction enzymes 
Restriction enzyme 
Incubation 
temperature and time 
Heat inactivation 
temperature and time 
KpnI-HF (10 U/ µL) (NEB#R0123S) 37°C/30 min N/A 
NotI-HF (10 U/ µL) (NEB #R3189S) 37°C/30 min 65°C/20 min 
HindIII-HF (10 U/ µL) (NEB#R3104S) 37°C/30 min 80C/20 min 
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 Primer sequences 
Table 2. List of primer sequences 
Primer name Primer consensus 
FMC63 forward CGG GCC CTC TAG ACT CGA GCG GCC GCC ACC 
FMC63 reverse TGA GGA GAC TGT GAC TGA GGT TCC TTG GCC 
MuFc SOE forward GGT ACC TGT AAG CCT TGC ATA TGT ACA GTC CCA GAA 
GTA TCA TCT GTC TTC ATC TTC CCC 
MuFc SOE reverse CAC AAA GCT TCG AGG ATC CTC ATT TAC CAG GAG AGT 
GGG AGA G 
TT2 reverse AGT CAA AGC TTG GAT CCT TAG TAC TGT TCC 
BGH reverse TAG AAG GCA CAG TCG AGG 
 
 Cell lines 
Table 3. List of cell lines 
Cell line Cellular Origin Species Notes 
HEK293 Embryonic kidney Human Media: 10% FCS/DMEM 
HEK293:CAR Embryonic kidney Human Transfected with anti-CD19 CAR: pSBbiRP 
Media: 10% FCS/DMEM 
Jurkat T Lymphocyte Human ATCC TIB-152.  
Media: R10 
Jurkat:CAR T Lymphocyte Human Transfected with anti-CD19 CAR: pSBbiRP.  
Media: R10 
Expi293F Embryonic kidney Human Media: Expi293 expression media 




Table 4. List of antibodies 
Target Conjugation Clone Isotype Source 
Mouse IgG Horse radish peroxidase 
(HRP) 
Polyclonal Goat IgG Sigma #A-4416 
Mouse IgG Alexa Fluor 488 (AF488) Polyclonal Goat IgG Invitrogen #A-11029 
α-c-myc Biotin 9E10 Mouse IgG1 Biolegend #908805 
 
 Reconstitution of primers 
Primers and geneblocks were ordered from Integrated DNA Technologies (IDT). Upon receipt, 
primers were reconstituted to 100 ng/µL and geneblocks to 10 ng/µL with sterile milliQ H2O. 
 Restriction enzyme digest and dephosphorylation 
All restriction enzyme digests were carried out at the temperature and incubation times outlined 
in Table 1. In general, 1 µg of DNA was diluted in a PCR tube with 1× Cutsmart buffer (New 
England Biolabs (NEB) #B7204S), 10 U of the appropriate restriction enzyme(s) and diluted with 
milliQ H2O for a total reaction volume of 40 µL. The reaction mix was then incubated at the 
temperature corresponding to the optimal conditions of the restriction enzyme(s) (Table 1). 
Plasmid digests were then subjected to gel electrophoresis on a 1% agarose gel. Appropriately 
sized bands were excised and purified using a DNA gel extraction kit as described in method 2.10. 
 Splicing by overlap extension (SOE) PCR 
Overlap extension PCR was used to splice together two PCR products through the introduction 
of complementary overlaps in a two-step process. The first step involved a PCR of the two genes 
of interest to introduce complementary overlaps. 100 ng of DNA for each gene was added to a 
PCR mixture containing 1× Q5 reaction buffer, 1 µL dNTP, 1× GC enhancer, 1 U of Q5 DNA 
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polymerase and 25 pmol of the appropriate forward and reverse primers (Table 2) with the mixture 
made up to 50 µL with milliQ H2O. Gene amplification was then performed with the following 
PCR protocol: 98C for 30 s; 20 cycles of 98C for 20s, 60C for 20 s, 72C for 1 min; 72C for 
2 min. The amplified gene products were then subjected to gel electrophoresis on a  
1% agarose gel and DNA bands extracted. The second step involved a PCR in which the two 
genes now containing complementary overlaps were ligated together and amplified. A PCR 
reaction mix was prepared as mentioned above containing 200 ng of each extracted PCR product, 
however, no primers were added for this step. To allow for the two genes to anneal this reaction 
mix was then subjected to the following PCR protocol: 98C for 30 s; 10 cycles of 98C for 20 s, 
50C for 20 s, 72C for 30 s; 72C for 2 min. The reaction mix then had 25 pmol of the appropriate 
forward and reverse primers added and subjected to the following PCR protocol to allow for 
amplification of the annealed gene: 98C for 30 s; 30 cycles of 98C for 20 s, 60C for 20 s, 72C 
for 1 min; 72C for 2 min. The PCR product was subjected to gel electrophoresis on a 1% agarose 
gel and appropriately sized bands gel extracted as described in method 2.10. 
 Gel electrophoresis 
Agarose gels (SeaKem®LE agarose (Lonza #50004); percentage as stated; 50 mL) contained  
1× TAE buffer and 1× SYBR® Safe DNA gel stain (Invitrogen #S33102). DNA samples 
containing 1× DNA loading dye (NEB #B7024S) or 6 µL of purple 1 kb plus DNA  
ladder (NEB #N05505) were loaded into wells and subjected to gel electrophoresis at 90 V,  
300 mA for 30 min in 1× TAE buffer. Gels were then visualised using an Odyssey Fc imaging 
system (LI-COR Biosciences) using the 600 nm light channel. 
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 Agarose gel DNA extraction 
DNA was extracted from agarose gel using a Monarch gel extraction kit (NEB #T10205) as per 
the manufacturer’s instructions. Briefly, the band of interest was excised from the gel using a 
scalpel and incubated for ~10 min at 50°C in a 4× volume of ‘Gel Dissolving Buffer’ per 100 mg 
of extracted gel. Tubes containing agarose gel were vortexed periodically to ensure complete 
dissolution of agarose. The DNA was then loaded into a filter column via centrifugation  
at 16 000 ×g for 1 min before being washed twice with 200 µL of ‘DNA Wash Buffer’ via 
centrifugation at 16 000 ×g for 1 min. The filter column then had 20 µL of ‘Elution Buffer’ added 
to the filter and incubated for 1 min at room temperature (RT) prior to a final centrifugation at  
16 000 ×g for 1 min to elute DNA into a clean 1.5 mL microfuge tube. 
 Ligation of DNA 
Purified digested plasmid DNA or gene inserts were ligated via incubation at 20°C for 1 h or 
overnight at 16°C. Ligations were carried out in 20 µL volume composed of 1× T4 Ligase 
Reaction Buffer (NEB #B0202S) and 10 U of T4 DNA ligase (NEB #M0202s). Insert and vector 
DNA were added to the reaction at an approximate DNA ratio of 2:1. 
 Calcium chloride competent Escherichia coli (E.coli) 
A 2 mL volume of LB media was inoculated with a colony of Top10 E. coli and incubated 
overnight at 37°C with shaking (200 rpm). This starter culture was added to 200 mL LB media 
and incubated as above until an OD600nm of ~0.4 was reached. The culture was incubated on ice 
for 20 min then centrifuged at 2000 ×g, 4°C for 10 min. The pellet was resuspended in 20 mL of 
pre-cooled 75 nM CaCl2/10 mM 1,4-Piperazinediethanesulfonic acid/15% glycerol, incubated on 
ice for 20 min and centrifuged as above. The pellet was resuspended in 2 mL pre-cooled  
75 nM CaCl2/10 mM 1,4-Piperazinediethanesulfonic acid/15% glycerol solution and aliquoted 
into pre-cooled (-80°C) microfuge tubes and stored at -80°C. 
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 Transformation of bacteria via heat shock 
CaCl2-compentent E. coli TOP10 were incubated on ice for 30 min with either 100 ng of plasmid 
DNA or 5 µL of ligation mix. The bacteria were then heat shocked for 90 s in a 42°C water bath 
and immediately incubated for a further 5 min on ice. The bacteria were added to 1 mL of LB 
broth pre-warmed at 37°C and incubated for 1 h at 37°C with shaking (200 rpm) to allow for 
recovery. Following recovery, 100 µL of bacteria was spread on to an LB agar plate with  
100 µg/mL ampicillin (AppliChem #A0839,0025) and incubated overnight at 37°C. 
 Colony PCR 
Bacterial colonies were sampled with the end of a sterile 10 µL pipette tip and used to inoculate 
a 15 µL PCR master mix, and then streaked onto an agar plate supplemented with 100 µg/mL 
ampicillin. This was repeated for 10 colonies per construct. The PCR mix contained 250 nM of 
appropriate forward and reverse primers and 1× Taq PCR master mix diluted in milliQ H2O. 
Amplification of the transformed plasmid was then performed with the following PCR protocol: 
95C for 2 min; 35 cycles of 95C for 30 s, 54C for 30 s, 72C for 1 min/kb; 72C for 5 min. The 
PCR products were then gel electrophoresed on a 1% agarose gel and visualised using the Odyssey 
Fc imaging system (LI-COR Biosciences) at 600 nm. 
 Miniprep plasmid purification 
Plasmid DNA was purified using the Monarch Plasmid DNA miniprep kit (NEB #T1010L) 
according to the manufacturer’s instructions. In brief, a l mL overnight culture of bacteria was 
centrifuged at 16 000 ×g for 5 min. All subsequent centrifugation steps were performed at  
16 000 ×g. Supernatant was then removed, and pelleted bacteria resuspended in 200 µL of 
‘Plasmid Resuspension Buffer’. Bacteria were then lysed through the addition of 200 µL of 
‘Plasmid Lysis Buffer’, inverted 3-5 times and incubated at RT for 1 min. The bacterial lysate 
was then neutralised through the addition of 400 µL of ‘Plasmid Neutralisation Buffer B3’ and 
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mixed by inversion before incubation for 2 min at RT. The neutralised lysate was centrifuged for 
5 min, supernatant removed and added to a filter column and centrifuged for 1 min. The DNA 
was washed through the addition of 200 µL of ‘DNA Wash Buffer 1’ and centrifuged for 1 minute. 
DNA was then washed again through the addition of 400 µL of ‘DNA Wash Buffer 2’ and 
centrifuged for 1 min. Finally, DNA was eluted from the filter column through the addition of  
30 µL of ‘DNA Elution Buffer’, incubation at RT for 1 min and centrifugation for 1 min. DNA 
concentration was determined using the Nanodrop ND-1000 at 260 nm. 
 Midiprep plasmid purification 
To allow for high yield purification of plasmid DNA the NucleoBond Xtra Midi Plus (Macherey-
Nagel #740412.50) was used as per the manufacturer’s instructions. In brief, a single E. coli 
TOP10 colony deemed to contain the correct plasmid based on colony PCR and DNA sequencing 
was used to inoculate a 150 mL culture of LB broth containing 100 µg/mL ampicillin. The culture 
was incubated at 37°C with 200 rpm shaking for 16-18 h. The culture was then centrifuged at 
6000 ×g for 20 min at 4°C, supernatant was removed, and the pellet resuspended in 8 mL of 
‘Resuspension Buffer Res with RNAse A’. Bacteria were then lysed through addition of an equal 
volume of ‘Lysis Buffer LYS’ and incubation at RT for 5 min. 
Lysate was neutralised through the addition of an equivalent volume of ‘Neutralisation Buffer 
NEU’ before being loaded onto a filter column pre-equilibrated with 12 mL of ‘Equilibration 
Buffer EQU’. Plasmid DNA was then washed from the filter with 5 mL of ‘Equilibrated Buffer 
EQU’, the filter removed and the column then washed with 8 mL of ‘Wash Buffer WASH’. DNA 
was then eluted from the column through the addition of 5 mL of ‘Elution Buffer ELU’. DNA 
was precipitated through the addition of 0.7 volumes of isopropanol, vortexed well and incubated 
at RT for 2 min. The DNA precipitation solution was loaded into a NucleoBond Finalizer and 
washed with 2 mL of 70% ethanol. The finalizer was air-dried to remove residual ethanol and 
DNA eluted using ‘Redissolving Buffer TRIS’. DNA concentration was determined using a 
NanodropND-1000 at 260 nm. 
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 Cell culture 
Cells stored in liquid nitrogen were thawed in 10 mL of the appropriate media (Table 3) then 
centrifuged at 453 ×g for 5 min. For human embryonic kidney 293 (HEK293) or NS0 cells,  
the pellet was then resuspended in 10 mL of media and transferred to a T75 cell culture flask 
(Thermo #156499) and incubated at 37°C with 5% CO2. Cells were maintained at a concentration 
of ~1.5 × 106 cells/mL. For planktonic Expi293F cells, the pellet was then resuspended in 15 mL 
of Expi293F expression media (Gibco #A1435101), transferred to a 125 mL Erlenmeyer flask 
and incubated with shaking (120 rpm) at 37C with 8% CO2. 
 Expi293F transfection 
To allow for expression of fragment crystallisable (Fc) fusion protein for immunisation and 
screening, planktonic Expi293F cells were transfected using the Gibco Expifectamine™293 
transfection kit (Gibco #A14524) according to manufacturer’s instruction. In brief, 40 µL of 
Expifectamine™293 reagent was diluted in 750 µL of Opti-MEM media (Gibco #31985062), 
mixed thoroughly by pipetting and incubated at RT for 5 min. During this incubation time 15 µg 
of plasmid DNA was diluted in a final volume of 750 µL of Opti-MEM media. Following the  
5 min incubation the two volumes were combined, mixed by pipetting and incubated at RT for 
20-30 min. The resulting DNA-expifectamine complexes were then added to 37.5 × 106 Expi293F 
cells diluted in 12.675 mL of fresh Expi293F expression media and incubated with shaking  
(120 rpm) at 37°C with 8% CO2. Enhancers were added 16-18 h post transfection (75 µL of 
enhancer 1, 750 µL of enhancer 2). Cells were incubated as stated to give a total incubation time 
of 120 h. 
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 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
To ensure the purity of scFv fusion protein prior to immunisation of mice, an elution fraction from 
a protein A column was run on 4-12% BOLT Bis-Tris gel (Invitrogen #NW0412A). 1 µg of 
protein was diluted to a volume of 20 µL with 1× BOLT sample buffer (Invitrogen #B0007) and 
PBS. For reduced protein, samples additionally contained 1× BOLT Sample Reducing Agent 
(Invitrogen #B0009) and were boiled for five minutes before placing on ice. Samples, or 6 µL of 
pre-stained protein standard (SeeBlue Plus2, Invitrogen #LC5925) were loaded into gels and run 
for 35 min at 200 V, 300 mA with BOLT MOPS SDS Running Buffer (Invitrogen #B0002). 
 Coomassie blue staining 
In order to visualise protein bands in SDS-PAGE gels, ~15 mL of Coomassie G-250 was 
incubated with the gel for 20 min at RT with rocking. Stain was then removed and gels destained 
through the addition of ~15 mL of Coomassie destain before being heated for 15 s in the 
microwave. The destaining step was repeated until bands were clearly distinguishable and 
significant background staining had been removed. Gels were imaged using the Li-Cor Odyssey 
Fc instrument at 700 nm. 
 Purification of antibody single chains by agarose bead columns 
The purification of Fc fusion proteins was performed using a Thermo™ scientific Pierce 
Chromatography Protein A (#20356) or Protein G (#89926) columns according to manufacturer’s 
instructions. In brief, Expi293F cell supernatant was removed, centrifuged at 453 ×g for 5 min to 
pellet cells, before centrifugation of supernatant at 2000 ×g for an additional 20 min at 4°C to 
pellet cellular debris, supernatant was finally 0.2 µm filter sterilised. Both protein A or G columns 
were washed with 10 mL volumes of binding solution, PBS for protein A or 50 mM sodium azide 
(pH 5.0) for protein G respectively. All steps were performed with a flow rate of 1 mL/min. Filter 
sterilised cell supernatants were then loaded onto the columns. Protein A columns then underwent 
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a two-step washing process with 10 mL volumes of 100 mM Tris (pH 8.0) followed by  
10 mM Tris (pH 8.0). Protein G columns were washed with 10 mL volumes of 50 mM sodium 
azide (pH 5.0). The Fc fusion proteins were then eluted from the columns in 500 µL fractions 
with 100 mM glycine (pH 3.0) and collected in microfuge tubes contain 100 µL of 1 M Tris-HCl 
(pH 9.0). Fractions were mixed to ensure neutralisation and the concentration of Fc fusion protein 
measured using the NanodropND-1000 at A280.  
 Lipofectamine transfection of HEK293 cells 
To generate anti-CD19 CAR expressing HEK293 cells the lipofectamine 3000 transfection kit 
(Invitrogen #L300015) was utilised as per manufacturer’s instructions. In brief, HEK293 cells 
were seeded at 4 × 105 cells per well in 6-well plates and maintained in 2 mL of 10% FCS/DMEM. 
Cells were incubated overnight at 37°C, 5% CO2. For each well to be transfected, 125 µL of  
Opti-MEM media (Gibco #31985070) and 7.5 µL of lipofectamine 3000 were combined and 
incubated for 5 min at RT. During incubation, 125 µL Opti-MEM, 5 µL P3000 reagent and 2.5 
µg of DNA were combined per well to be transfected. The 2.5 µg of DNA consisted of a 5:1 ratio 
of pSBbiRP plasmid and pCMV(CAT)T7-SB100 transposase plasmid. The two volumes were 
then combined and incubated for a further 15 min at RT, before 250 µL volumes of the combined 
mixture was then added to each well before incubation overnight at 37°C, 5% CO2. Efficiency of 
transfection was assessed via the expression of red fluorescent protein (RFP) via fluorescent 
microscopy. 
 Immunisation of mice with FMC63 antigen 
BALB/c mice originally obtained from The Jackson Laboratory, Bar Harbor, ME, USA were bred 
at the Hercus-Taieri Resource Unit (HTRU), University of Otago, Dunedin, NZ, under specific 
pathogen free conditions. Naïve BALB/c female mice approximately eight weeks of age were 
immunised with either Fc fusion protein, or HEK293:CAR expressing cells. All immunisations 
were performed by HTRU staff under the appropriate Animal User Protocol approved by the 
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University of Otago Animal Ethics Committee. Mice were immunised three times with 20 µg of 
Fc fusion protein, twice intraperitoneally (IP; 200 µL volume; 23 G needle) with a 1:1 ratio of 
protein/PBS with either Freund’s complete adjuvant (FCA; 1st IP; day 0), or Freund’s incomplete 
adjuvant (FIA; 2nd IP; day 14) emulsified by vortexing. To assess the antibody response level, on 
day 26, blood samples were taken as described in method 2.22, prior to administration of the third 
immunisation (day 28) of 20 µg of Fc fusion protein via intravenous (IV) injection to the lateral 
tail vein (100 µL volume; 31 G needle) diluted in PBS. Alternatively, naïve BALB/c female mice 
were immunised twice (days 0 and 14) with 1 × 106 HEK293:CAR cells via intraperitoneal 
injection (200 µL volume; 23 G needle). HEK293:CAR cells were prepared by washing cells 
twice in 5 mM EDTA/PBS before resuspension at 5 × 106 cells/mL in PBS. 
 Blood sampling 
Blood samples (30-40 µL) were taken following a ~1 mm scalpel incision to the tail tip. Blood 
was allowed to clot at RT overnight, after which serum was removed and analysed by an enzyme-
linked immunosorbent assay (ELISA) for assessment of the antibody response. 
 Generation of hybridomas 
To generate immortal cells secreting a single specificity mAb, splenocytes of immunised mice 
were fused with NS0 mouse myeloma cells. Immunised mice were euthanised by CO2 
asphyxiation three days following the third immunisation i.e. day 31. Spleens were removed 
aseptically and placed into sterile PBS. Harvested spleens were then teased out and filtered using 
a 70 µm cell strainer with PBS. Splenocytes were centrifuged at 453 ×g for 5 min and supernatant 
removed. The pellet was then resuspended in 50 mL of PBS and a 20 µL sample taken for cell 
counting before centrifugation at 453 ×g for 5 min. Cells were counted with a Neubauer 
haemocytometer slide using a 1:1 ratio of cell suspension to 0.3% trypan blue dye. The desired 
ratio of splenocytes to NS0 cells was 5:1, with the appropriate number of NS0 cells harvested and 
centrifuged at 453 ×g for 5 min. The splenocytes and NS0 pellet were combined and resuspended 
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in 10 mL of RPMI without FCS (R0) before centrifugation at 453 ×g for 5 min. Supernatant was 
removed and the pellet resuspended in residual R0 by tapping the tube. The tube was then placed 
in a 37°C water bath and 1 mL of pre-warmed 50% polyethylene glycol 1500 solution (Roche 
#10783641001) added to the cells over a 1 min period whilst the solution was gently mixed. The 
solution was mixed for a further 1-2 min before a 13 mL volume of pre-warmed R0 was added, 
with the first 3 mL added over 3 min and the remaining 10 mL over 1 min. The cell suspension 
was incubated in a 37°C water bath for 5 min. Each splenocyte/NS0 mixture was resuspended in 
200 mL of R10 media supplemented with 1× hypoxanthine-aminopterin-thymidine (HAT) (Gibco 
#21060-017) before plating 200 µL/well of the resuspended mixture into a 96-well flat bottom 
plate. Plates were incubated at 37°C with 5% CO2. 
 Fc fusion protein ELISA 
Nunc 96-well flat bottom maxisorp plates (50 µL/well ) were coated with 2 µg/mL FMC:Fc or 
CR1:Fc fusion protein diluted in PBS and incubated overnight at 4°C. Plates were washed three 
times with 0.05% Tween20/PBS (300 µL/well), before blocking with 1% FCS/PBS (100 µL/well) 
for 10 min at RT. Blocking solution was removed from wells by flicking. Hybridoma cell 
supernatant (50 µL/well) was then added to the plate and incubated at 37°C for 1 h. The plate was 
then washed three times in 0.05% Tween20/PBS and incubated with goat anti-mouse (GAM) IgG 
HRP diluted 1/1000 in 1% FCS/PBS (50 µL/well) at 37°C for 1 h. The plate was then washed  
as described previously and developed with 3,3’,5,5’-tetramethylbenzidine (TMB) single  
solution (50 µL/well; Novex #00-2023). Once the reaction had developed sufficiently, the reaction 
was stopped with 2N H2SO4 (25 µL/well). Absorbance was measured at 450 nm with a Varioskan 
Lux microplate reader (Thermo #VL0000D0). 
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 Ig isotyping ELISA 
Nunc 96-well flat bottom maxisorp plates (Thermo #44-2404-21) were coated with anti-mouse 
IgA, IgM, IgG1, IgG2a, IgG2b or IgG3 mAb (Sigma #ISO2-1KT) diluted 1/1000 in  
PBS (50 µL/well) and incubated at 37°C for 1 h. Plates were washed three times with  
0.05% Tween20/PBS (300 µL/well), before blocking with 1% FCS/PBS (100 µL/well) for  
10 min at RT. Blocking solution was removed from wells by flicking. Hybridoma cell  
supernatant (50 µL/well) was then added to the plate and incubated at RT for 1 h. The plate was 
washed three times with 0.05% Tween20/PBS and incubated with GAM IgG HRP diluted 1/1000 
in 1% FCS/PBS (50 µL/well) at 37°C for 1 h. The plate was washed as described previously and 
developed with TMB single solution (50 µL/well). Once the reaction had developed sufficiently 
the reaction was stopped with 2N H2SO4 (25 µL/well). Absorbance was measured at 450 nm with 
a Varioskan Lux microplate reader. 
 Antibody production in a bioreactor 
Approximately 25 × 106 hybridoma cells were pelleted via centrifugation at 453 ×g for 5 min and 
resuspended in 15 mL of 10% FCS (Ig depleted with Protein G column)/Iscove's Modified 
Dulbecco's Media (IMDM; Gibco # 12440-061) supplemented with 100 U/mL penicillin,  
100 µg/mL streptomycin and 55 µM BME. The resuspended cells were then added to the inner 
chamber of a two-compartment bioreactor (Sigma #Z688029) and air bubbles removed. The outer 
compartment was then filled with 500 mL of 2% FCS/IMDM supplemented with 
penicillin/streptomycin and BME at the same dilution as above. Bioreactors were incubated at 
37C with 5% CO2 for ~10 days until the majority of cells were observed to be apoptotic. The 
media was then removed from the outer compartment and discarded. The media was removed 
from the inner compartment, and this compartment washed twice with 10 mL of sterile PBS. The 
media and PBS were centrifuged at 453 ×g for 5 min to pellet cells. Supernatant was then 
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centrifuged at 2000 ×g for 20 min at 4C to pellet cellular debris. Finally, the supernatant was 
then clarified through 0.22 µm filtration and stored at 4C until ready to be precipitated. 
  Precipitation of murine IgG 
Supernatant was collected from hybridoma cultures, either from T75 flasks or bioreactor 
concentrators. The supernatants were 0.22 µm filtered to remove any debris and stored at 4°C 
until required for use. Ammonium sulphate (Scharlua #AM0400) was added to the supernatant at 
27.7 g/100 mL to provide a 45% saturation before stirring for 15 min at RT. The solution was 
then incubated for 2 h at 4°C before centrifugation at 10 000 ×g for 30 mins. The supernatant was 
discarded, and the pellet resuspended in ~5 mL of PBS before dialysed against a 500 mL volume 
of PBS. Dialysis was performed for at least five buffer changes with a minimum of 2 h between 
buffer changes. Protein concentration was determined with a NanodropND-1000 at A280. 
 Precipitation of murine IgM 
Cell supernatant containing murine IgM was not able to be sufficiently precipitated using 
ammonium sulphate precipitation, so an alternative method was employed. Supernatant was  
0.22 µm filtered to remove debris. Sterilised supernatant was then loaded into dialysis tubing and 
dialysed against 500 mL volumes of milliQ H2O for at least five buffer changes with at least 2 h 
between changes. When Ig precipitation was observed within the dialysis tubing, the dialysed 
supernatant was removed and the precipitated pellet was resuspended in PBS. The resuspended 
pellet was then centrifuged at 10 000 ×g to pellet protein and remove soluble impurities.  
Pelleted Ig was resuspended again in PBS. Protein concentration was determined with a 
NanodropND-1000 at A280. 
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 Fluorescein conjugation of monoclonal antibodies 
N-Hydroxysuccinimide (NHS)-fluorescein (Pierce #46410) was reconstituted to 10 mg/mL in 
100 µL of dimethyl sulfoxide (Sigma # D2650-100ML). Diluted NHS-fluorescein (4.7 µL per 1 
mL of protein) was added to purified mAb (1 mg/mL). Samples were incubated with shaking at 
RT for 1 h. Conjugated mAb was then dialysed twice against 500 mL volumes of 100 mM 
glycine/PBS to quench the reaction. A total of six further rounds of dialysis were performed 
against 500 mL volumes of PBS. Buffer changes were at least two hours apart. 
 Staining of cells for flow cytometry 
Jurkat:anti-CD19 CAR cells, or untransfected controls (2 × 106/tube) were washed with ~1 mL of 
0.1% FCS/PBS. Tubes were then centrifuged at 453 ×g for 5 min to pellet cells and the supernatant 
discarded. Pellets were resuspended and incubated for 30 min on ice with 50 µL of either 
hybridoma cell supernatant, purified Ig from hybridoma supernatant (2.5 µg/mL; unconjugated or 
fluorescein-conjugated), or 0.1% FCS/PBS. Cells were washed by the addition of 1 mL of  
0.1% FCS/PBS before centrifugation at 453 ×g for 5 min and supernatant discarded. To detect 
unconjugated Ig, pellets were resuspended and incubated with 50 µL of 2.5 µg/mL GAM IgG 
AF488 secondary antibody on ice for 15 min. Cells were washed as previously described. All 
pellets were resuspended in 200 µL of 0.1% FCS/PBS and then analysed by flow cytometry. 
 Flow cytometric analysis 
Flow cytometric analysis was performed using a BD LSRFortessa flow cytometer with BD 
FACSDiva software. The voltages used for each experiment were set as appropriate using a 
combination of single stained, unstained and untransfected controls. Compensation was calculated 
using BD FACSDiva software. FlowJo version 10.2 software was used to analyse the data with 
gating of live cell populations using forward scatter versus side scatter  then subject to forward 
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scatter and side scatter single cell discrimination, prior to analysis based on the appropriate 
fluorophores. 
 DNA sequencing 
DNA was sequenced by the Genetic Analysis Services, Department of Anatomy, University of 
Otago. DNA (150 ng) was amplified using 3.2 pmol/5 µL of each appropriate forward and reverse 
primer. DNA was sequenced with an ABI 3720x1 DNA analyser. 
 Data analysis and presentation 
Images from Coomassie and SYBRSafe stained gels were analysed in Image Studio Lite 5.2 
software, and DNA sequencing was analysed using Geneious 9.13 software. ELISA data was 
analysed and/or graphed using GraphPad Prism 8.0.2 software. Flow cytometry data was 





Chapter Three: Results 
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3.1 Cloning of FMC-huFc fusion protein 
A widely utilised method to generate mAb is through immunisation of mice to generate 
hybridomas. To achieve this for the generation of anti-CAR mAb it was necessary to express a 
soluble form of the FMC63 scFv. To achieve this, an Fc region containing the CH2 and  
CH3 constant domains of IgG1 was cloned to generate an Fc fusion protein. This both provides 
improved stability and allows for simple purification of Fc fusion proteins based on the presence 
of an Fc region. To provide alternatives for screening and immunisation of mice, two Fc  
regions – murine (muFc) and human (huFc) IgG1 – were utilised. The pcDNA3.1(-) vector was 
selected for the expression of the Fc fusion proteins as it represents a well characterised platform 
for the transient expression of recombinant proteins in mammalian systems.  
The FMC63 scFv was digested from the anti-CD19 CAR: pSBbiRP plasmid using NotI and KpnI 
restriction enzymes. The digested product was gel electrophoresed and the appropriate band at 
801 bp was extracted (Figure 3B). The huTFFc: pcDNA3.1(-) plasmid, encoding a tissue factor 
antigen ligated to a huFc Ig domain, was digested with NotI and KpnI restriction enzymes.  
This digestion removed the tissue factor antigen from the vector, seen as the ~600 bp band in 
Figure 3B. This generated a backbone with a huFc region and complementary NotI and KpnI 
restriction overlaps for insertion of the digested FMC63 scFv. The ~6 kb band containing the 
digested backbone was extracted from the agarose gel and ligated to the FMC63 scFv gene insert. 
Ligated vector DNA was transformed into Top10 E. coli and colony PCR performed to identify 
colonies containing the vector of interest. Of the ten colonies screened in the colony PCR, nine 
showed a band at the appropriate length of ~1.5 kb (Figure 3C). Plasmid DNA was purified from 
the colonies corresponding to lanes 1, 4, 5 and 9, subsequent sequencing of the corresponding 
plasmid DNA showed that all plasmids contained the correct gene encoding FMC63 scFv huFc 
fusion protein (FMC-huFc). Colony 2 was selected for use with fusion protein expression. 
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Cloning of FMC63 scFv muFc fusion (FMC-muFc) protein utilised the CR1-muFc pcDNA3.1(-) 
vector as a backbone. Unlike the huTFFc: pcDNA3.1(-) vector, a single step removal of antigen 
and replacement with FMC63 scFv was not possible, instead a two-step approach was required. 
The CR1-muFc backbone was restriction digested with NotI and KpnI and gel electrophoresed. 
This resulted in the digestion of CR1 antigen and muFc from the backbone, shown as two bands 
at ~600 and ~800 bp respectively (Figure 3B). The muFc gene was gel extracted from the ~800 
bp band (Figure 3B). The FMC63 scFv was digested as above, and then ligated to the muFc gene. 
This FMC-muFc gene insert was then ligated to the previously extracted pcDNA3.1(-) backbone. 
The ligated plasmid product was transformed into TOP10 E. coli and colony PCR performed to 
identify colonies containing the vector of interest. Ten total colonies were screened, with 
amplification observed in eight of the ten colonies. This amplification showed a band at ~1100 
bp, while the correct gene represents a ~ 1.5 kb band. 
An undigested CR1-muFc vector control was included in a second screen of a further ten colonies. 
Again, eight colonies showed amplification at ~1100 bp, as did the vector control (Figure 3D). 
Analysis of primers used with Geneious software indicated that the FMC63 forward primer used 
in colony PCR bound at a multiple cloning site (MCS) to generate a ~1100 bp band, indicating 
that the amplification observed was from colonies that had been transformed with undigested 
plasmid. The above experiments were unsuccessfully repeated three times before it was decided 
to utilise an alternative technique to generate a FMC-muFc fusion protein encoding gene. 
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Figure 3. Gel electrophoresis images of NotI and KpnI restriction digestion and colony PCR of 
FMC63-huFc fusion protein. 
Restriction digested DNA was run on 1% agarose gel and SYBRSafe DNA dye imaged with a  
Li-Cor Odyssey Fc instrument at 600 nm. 
(A) NotI and KpnI digested huTFFc:pcDNA3.1(-) plasmid for cloning. Lane 1 DNA ladder;  
lanes 3-4 and 6-7 digested huTFFc: pcDNA3.1(-). The digested backbone was extracted from the 
~5 kb band observed in lanes 3-4 and 6-7. 
(B) NotI and KpnI digested CD19CAR: pSBbiRP and CR1muFc: pcDNA3.1 plasmids for 
cloning. Lane 1 DNA ladder; Lane 2-4 digested CD19CAR: pSBbiRP; Lane 6-8 digested 
CR1muFc: pcDNA3.1(-);. Digested FMC63 scFv and murine Fc were extracted from the 801 and 
694 bp bands in lanes 2-4 and 6-8 respectively. 
(C) Colony PCR of TOP10 E. coli colonies containing the FMC63-huFc fusion protein plasmid.  
Lane 1 DNA ladder; Lanes 2-11 TOP10 E. coli colonies transformed with FMC63-huFc fusion 
protein plasmid. All colonies in lanes 2-5 and 7-10 were observed to have the desired plasmid 
with a band at ~1500 bp.  
(D) Colony PCR of TOP10 E. coli colonies containing the FMC63-muFc fusion protein 
pcDNA3.1(-) plasmid. Lane 1 DNA ladder; Lane 3-11 TOP10 E. coli colonies transformed with 
FMC63-muFc fusion protein plasmid; Lane 12 CR1-muFc plasmid control. Lane 3 was observed 
to have a band at the desired size of ~1500 bp. 
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3.2 Cloning of FMC63-muFc fusion protein through overlap extension PCR 
Following the unsuccessful attempts to generate a FMC63-muFc gene through a two-step ligation, 
SOE PCR was selected to generate the desired gene. SOE PCR involves the introduction of a 
short region of homology at the ends of two genes of interest using specially designed primers. 
These regions of homology are then used to anneal the two genes together. The resulting overlaps 
are then used as internal primers for the amplification of the annealed genes to generate the desired 
final product consisting of the two genes.  
The FMC63 scFv and muFc genes were amplified with the appropriate SOE PCR  
primers (Table 2), introducing a 30 bp overlap in the hinge region. The PCR products were gel 
electrophoresed and extracted from the ~800 and ~600 bp bands respectively. To anneal the two 
genes at the newly introduced overlap regions a PCR reaction without primers was first 
performed. The FMC63 forward and muFc reverse primers were then added to the PCR reaction 
to amplify the ligated gene. The PCR product was gel electrophoresed and the ~1.5 kb band 
representing the ligated FMC63-muFc gene extracted (Figure 4A). 
The vector and the FMC-muFc gene insert were NotI and HindIII restriction digested to generate 
a backbone and insert with the appropriate restriction overlaps, these were then ligated and 
transformed into TOP10 E. coli. Colony PCR was performed to identify colonies containing  
the desired vector. All ten colonies screened showed amplification of the ~1.5 kb insert,  
indicating that the correct plasmid DNA was present (Figure 4B). Plasmid DNA was purified 
from colonies 2, 3 and 9, subsequent sequencing showed that all plasmids contained the correct 





Figure 4. Gel electrophoresis of FMC63 murine Fc SOE PCR cloning and colony PCR.  
PCR products from SOE PCR and colony PCR reactions were subjected to gel electrophoresis on 
a 1% agarose gel. 
(A) SOEing PCR product of FMC-muFc fusion protein reaction and digested vector backbone.  
Lane 1 DNA ladder; Lane 3-4 SOE PCR product; Lane 6-7 NotI and HindIII digested CR1-muFc: 
pcDNA 3.1 (-) vector backbone. DNA was extracted from the ~1.5 kb and ~6 kb bands from lanes 
3-4 and 6-7 respectively. 
(B) Colony PCR of TOP10 E. coli colonies transfected with FMC63-muFc fusion protein 
pcDNA3.1(-) plasmid. Lane 1 DNA ladder; Lanes 3-12 Top10 E. coli colonies transfected with 
FMC63-muFc fusion protein plasmid. All colonies were observed to contain the correct sized 
band at ~1.5 kb. 
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3.3 Expi293F transfection and expression of Fc fusion proteins 
In order to generate soluble FMC63 scFv fusion proteins it was necessary to both express and 
purify the proteins. The Expi293F cell line is a planktonic HEK293F-derived cell line that has 
been previously used in the McLellan laboratory for transient expression of protein. Plasmid DNA 
encoding either FMC63-muFc or FMC63-huFc was transfected into the Expi293F cell line and 
incubated for 120 h to allow for protein expression. Fusion proteins were purified from cell 
supernatant based on the presence of an Fc region with columns containing either Protein A or 
Protein G coated agarose beads.  
Protein A and G columns have different Fc binding capabilities, with both columns used in an 
attempt to ensure effective purification of both human and murine fusion proteins. Protein was 
eluted in 500 µL fractions and the concentration determined by nanodrop (Figure 6A, 6B). The 
peak concentration for FMC63-huFc protein was 0.432 and 0.352 mg/mL in fractions eluted from 
protein A and G columns respectively (Figure 5A, 5B). The peak concentrations for FMC63-
muFc were considerably lower, 0.029 and 0.45 mg/mL for protein A and G columns respectively 
(Figure 6A, 6B). The amount of FMC63-huFc protein eluted was sufficient for use in subsequent 
immunisation of mice and screening of hybridomas. However, the low levels of FMC63-muFc 
eluted from the columns meant that alternatives were required for immunisation of mice to 





















Figure 5. Elution of FMC63 scFv fusion proteins containing murine and human Fc regions 
via protein A and G columns and examination of human Fc fusion protein purity. 
 Expi293F cells were transfected with plasmid DNA encoding FMC63 fusion protein with either 
murine or human IgG1 Fc regions for 120 h. Cell supernatant was collected and fusion protein 
was isolated with columns containing either protein A or G coated agarose beads, (A) or (B) 
respectively. Bound fusion protein was eluted at pH 3.0 in 500 µL fractions of 100 mM glycine, 
with neutralisation with 100 µL of 1M Tris-HCl. Protein concentration measured with a Nanodrop 
at 280 nm. (C) Protein A purified FMC63-huFc fusion protein were run on a 4-12% Bis-Tris SDS 
gel in MOPS buffer, Coomassie stained and de-stained, then visualised with the Li-Cor Odyssey 
Fc instrument at 700 nm. Lane 1, Protein ladder; Lane 2, non-boiled, non-reduced FMC63-huFc 
fusion protein; Lane 3-5, blank wells. Lane 6, protein ladder; Lane 7, boiled, reduced  
FMC63-huFc fusion protein. (D) Indirect ELISA screen of Expi293F supernatant for detection of 
FMC-muFc fusion protein. Plates were coated with α-mu IgG1 capture antibody and binding 
detected with GAM IgG HRP.  
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3.4 Generation of CAR expressing cells of immunisation of mice 
In order to immunise mice with FMC63 scFv in a second context, HEK293 cells were transiently 
transfected with the anti-CD19 CAR: pSBbiRP plasmid. This generated cells expressing a CAR 
containing an FMC63 scFv derived antigen recognition domain (HEK293:CAR). Transfection 
was performed using the lipofectamine 3000 transfection reagent. The plasmid encoding the anti-
CD19 CAR contained an RFP reporter gene that was used to examine the efficiency of 
transfection prior to use as an antigen. Cells were maintained for 48 h post-transfection before 
they were examined using fluorescence microscopy. Transfections were high-efficiency as shown 
by the near full expression of RFP in transfected cells (Figure 6). Transfected cells were harvested 


















Figure 6. Fluorescence images showing high-efficiency transfection of HEK293 cells with 
pSBbiRP: CD19 CAR plasmid. 
HEK293 cells were transfected with pSBbiRP plasmid encoding the FMC63 anti-CD19 CAR 
using the lipofectamine 3000 transfection system. Cells were maintained in media for 48 h and 
the transfection efficiency visualised using an RFP reporter gene. Fluorescence microscopy was 
used to visualise both (A) untransfected controls and (B) anti-CD19 CAR transfected cells under 
bright field or for RFP expression as indicated. Visualised under 10× objective; scale bar 

























3.5 Assessment of the anti-FMC63 immune response in immunised mice 
To assess the antibody response prior to euthanasia, serum samples were taken three days prior to 
the final FMC63 fusion protein or HEK293:CAR antigen immunisation of mice. Plate bound 
FMC63-huFc protein was used to detect FMC63 scFv reactivity within the serum by indirect 
ELISA. Mice that were immunised with huFc fusion protein were additionally screened against 
CR1-huFc fusion protein as a control to assess the level of reactivity against huFc. 
The fusion protein immunised mice (mouse A and B) both showed substantial reactivity against 
both the FMC63-huFc fusion protein, as well as the CR1-huFc fusion protein control. Moreover, 
both mice showed greater reactivity against FMC-huFc than the huFc control, indicating a FMC63 
scFv specific immune response had been generated (Figure 7). Naïve serum controls were also 
tested and showed no significant reactivity above the 1% FCS/PBS blocker background. These 
results were satisfactory to continue with the final IV immunisation with FMC63-huFc protein at 
d28 and sacrifice at d31. 
In comparison, HEK293:CAR immunised mice (mouse C and D) showed no significant reactivity 
against FMC63-huFc, with absorbance values equivalent to naïve serum controls and background 
blocker reactivity at all dilution ranges (Figure 8A, 8B). This indicated that no FMC63 scFv 
specific immune response was generated. Therefore, we restarted the immunisation schedule for 
these mice with FMC63-huFc. Following two subsequent IP injections of FMC-huFc protein, 
serum was re-tested by ELISA and significant reactivity against both FMC63-huFc and  
CR1-huFc was noted (Figure 8C, 8D). However, reactivity against the CR1-huFc control was 
considerably higher than reactivity against FMC63-huFc (Figure 8C, 8D). While these results did 
not indicate an FMC63 scFv specific immune response had been generated, due to time constraints 




















Figure 7. Assessment of serum reactivity of mice A and B to FMC63-huFc and CR1-huFc 
following FMC63 fusion protein immunisation .  
Serum was isolated from blood samples of mouse A (A) and B (B) following two IP injections of 
FMC63-huFc fusion protein. Serum antibody reactivity against FMC63-huFc and CR1-huFc was 
tested using an indirect ELISA, detected via GAM IgG-HRP and developed with TMB. Reactivity 
to FMC63 scFv was determined using FMC63-huFc fusion protein, while CR1-huFc served as a 
huFc control. Serum was diluted 1/3000 in 1% FCS/PBS and 1/3 dilutions performed within the 
ELISA plate from 1/3000 to 1/81000. Naïve serum of mouse A (pre-immunisation) was also 










Figure 8. Assessment of serum reactivity mouse C and D to FMC63-huFc following 
immunisation with HEK293:CAR. 
BALB/c mice were IP immunised twice with (A, B) 1 × 106 HEK293:CAR cells or (C, D)  
FMC6-huFc. Serum was isolated from blood samples of mouse C (A, C) and D (B, D), or a naïve 
BALB/c mouse. Serum antibody reactivity against plate bound FMC63-huFc antigen (A, B, C, 
D) and CR1-huFc (C, D) was tested by indirect ELISA, with mouse Ig detected with the secondary 
antibody GAM IgG-HRP and developed with TMB. Serum was diluted 1/3000 in 1% FCS/PBS 
and 1/3 dilutions performed within the ELISA plate from 1/3000 to 1/81000. Absorbance has not 
had 1% FCS/PBS background subtracted and the background value is shown all graphs. Bars 
indicate mean; error bars indicate SD.  
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3.6 Identification of hybridomas producing FMC63 scFv specific monoclonal  
antibodies (mAb) 
Following sacrifice, splenocytes of immunised mice were fused with the non-secretory mouse 
myeloma cell line, NS/0, to generate immortal antibody secreting hybridomas. Plates were 
incubated for ~14 days to allow for selection of fused hybridomas with HAT. This allowed 
hybridomas to grow sufficiently to identify those that had formed single colonies. A total of 3526 
wells were screened, with 368 single-colonies identified. 
Cell supernatant from single colonies was screened via an indirect ELISA to identify those 
secreting FMC63 scFv specific mAb. The cell supernatant was screened against both  
FMC63-huFc and CR1-huFc to assess the specificity of the mAb against either FMC63 scFv or 
huFc respectively. We arbitrarily set a absorbance ratio for mAb deemed to be FMC63 scFv 
specific: these were required to show ELISA absorbance readings to FMC63-huFc at levels twice 
that observed for binding to CR1-huFc (Figure 9). A total of 14 hybridomas were identified as 
secreting FMC63 scFv specific mAb, representing 3.8% of screened hybridomas (Figure 9). The 
analysis identified a number of distinct groups of hybridomas. Those identified to be non-
secretory were grouped at the lowest range of values for both CR1-huFc and FMC63-huFc 
absorbance. A distinct group of huFc binding hybridomas were observed at an approximate  
1:1 ratio of modest absorbance ranges slightly higher than those identified as non-secretory 
(Figure 9). Four high secreting anti-huFc hybridomas were identified with high 1:1 absorbance 
values for both fusion proteins. Additionally, in line with the serum reactivity tests of mice C and 
D, hybridomas from these spleens identified 10 CR1 specific mAb (3.0%). 
Following characterisation of mAb specificity, only the 14 hybridomas secreting FMC63 scFv 
specific mAb were retained and used for subsequent testing. These single colonies were re-cloned 
to ensure true monoclonality before further testing. This process saw only five hybridomas survive 
this process and re-form single colonies, likely due to variation in the number of cells for each 
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hybridoma. Successfully re-cloned hybridomas were tested again via indirect ELISA to ensure 
that they were still secreting mAb (Figure 10). In order for a single colony to be deemed secretory 
the absorbance readings were required to be 2.5 times that of the background level. Of the five 
hybridomas that were successfully re-cloned, all showed at least one single colony that fulfilled 
these criteria and were thus expanded for further testing. In the cases where a single hybridoma 
generated more than one single colony that fulfilled these criteria, colonies that were seen to have 
both robust secretion and considerable cell growth were retained. The hybridomas that remained 
represented those that secreted FMC63 scFv specific mAb, were truly monoclonal and had 




Figure 9. ELISA screen of hybridoma single colony supernatants to identify FMC63 scFv 
specific colonies. 
Cell supernatant from hybridoma single colonies was analysed by indirect ELISA against plate 
bound FMC63-huFc and CR1-huFc to assess mAb specificity to either FMC63 scFv or huFc 
respectively. Mouse Ig was detected with the secondary antibody GAM IgG-HRP and developed 
with TMB. Colonies that showed OD ratios > 2 when comparing FMC63-huFc and CR1-huFc 
were deemed to be scFv specific. 369 single colonies were screened in total, with 14 deemed to 
be FMC63 scFv specific – A1.B12, A2.D11, A2.G4, A10.G12, A11.B1, B3.D10, B5.A4, C6.G1, 
C3.H4, D1.E7, D3.E2, D4.G5, D5.G10, D7.B6. Due to limited cell supernatant availability 




Figure 10. Absorbances of hybridoma single colony cell supernatant following re-cloning to 
ensure monoclonality. 
Hybridoma single colonies observed to be FMC63 scFv specific were re-cloned to ensure 
monoclonality. Cell supernatant from single colonies were then screened against plate bound 
FMC63-huFc via an indirect ELISA to identify hybridomas with sustained mAb secretion. 
Hybridomas in which cell supernatant provided absorbance values 2.5 times higher than  
1% FCS/PBS background were deemed to be secreting sufficiently to be used for subsequent 
experiments. The threshold for secretion is represented by a dashed line. Anti-FMC63 serum from 
mouse A was screened at a 1/3000 dilution Seven single colonies representing five hybridomas 
satisfied these criteria. 
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3.8 Concentration and purification of FMC63 scFv specific mAb from hybridoma cell 
supernatant  
In order to ensure that potential binding of mAb to FMC63 scFv was not due to elements within 
cell culture media, mAb were purified from supernatant. This process also allowed for mAb to be 
concentrated to generate appropriate amounts for flow cytometric analysis. The isotype of an 
antibody has several implications, including the optimal method by which they can be purified. 
The isotype of the five secreted mAb was determined to ensure that appropriate purification 
methods were used. Cell supernatant from each of the seven hybridomas was subjected to an 
isotype ELISA, representing five distinct mAb (Figure 11). Of these, one was shown to be IgG1 
(A1.B11), while the other four were IgM (Figure 11). Concentration of mAb from hybridoma 
supernatant can be achieved through ammonium sulphate precipitation, followed by dialysis 
against PBS. This method was applicable to the hybridomas secreting IgG1 mAb, A1.B11.C3 and 
A1.B11.B5, however, this method is often not sufficient for IgM isotype antibodies.81 The 
remaining antibodies were purified through dialysis of supernatant against milliQ H2O, taking 
advantage of the low solubility of the IgM euglobulin in water.82 
Two mAb were also selected for concentration with a two-chamber bioreactor. This method 
allows for the mAb secreted by hybridomas to become heavily concentrated and is a typical 
method for generating large amounts of high concentration mAb from hybridomas. The two 
hybridomas selected to be concentrated in bioreactors were A11.B1.B5 and A1.D11.B12, 





Figure 11. Characterisation of mAb isotypes via indirect isotype ELISA. 
Supernatant from FMC63-huFc specific hybridomas was incubated with mAb specific for murine 
IgA, IgG1, IgG2a, IgG2b, IgG3, or IgM isotype antibodies. Binding of mAb was detected via 
GAM IgG HRP secondary antibody and developed with TMB. All absorbance readings have 
background 1% FCS/PBS absorbance removed. 
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3.9 Assessment of CAR-binding ability of FMC63 scFv specific mAb via flow cytometry 
The ideal quality control reagent for CAR T cell manufacture is capable of recognising the 
expression of CAR on the surface of transduced T cells. Having identified five mAb capable of 
recognising FMC63 scFv via ELISA, the final functional test was performed via flow cytometry. 
Screening was performed using the Jurkat T cell line, with untransfected controls and cells 
expressing an anti-CD19 CAR construct. The expression of the CAR was confirmed prior to flow 
cytometric testing via staining of a c-myc tag in the extracellular portion of the CAR construct 
with an anti-c-myc mAb. The increase in fluorescence observed between untransfected Jurkat 
cells and the anti-CD19 CAR transfected cells confirmed the surface expression of the CAR 
construct (Figure 12).  
Whole serum from both an immunised and naïve mouse was screened for binding to Jurkat cells 
expressing the anti-CD19 CAR construct. This allowed for the presence of mAb capable of 
binding to the CAR via flow cytometry following immunisation to be confirmed. An increase in 
fluorescence was seen for anti-CD19 CAR expressing cells following incubation with whole 
serum from the immunised mouse (Figure 13J, 13K, 13L). This showed that the immunisation 
protocol utilised was able to generate mAb capable of detecting anti-CD19 CAR expression via 
flow cytometry. 
Purified hybridoma mAb were fluorescently labelled with NHS fluorescein to allow for direct 
detection of mAb binding via a fluorescent conjugate. The efficient labelling of purified mAb was 
confirmed through the use of anti-mouse beads (Figure 15). These mAb were then incubated with 
both untransfected Jurakt cells as well as those expressing the CD19 CAR. There was no increase 
in fluorescence seen for any of the mAb following incubation with CD19 CAR expressing Jurkat 




















Figure 12. Analysis of CAR surface expression via flow cytometry.  
Flow cytometry was used to measure the surface expression of anti-CD19 CAR via the c-myc tag 
present in the extracellular domain, and the RFP reporter gene that indicates transfection with the 
pSBbiRP plasmid.  
(A) Untransfected Jurkat or (B) Jurkat cells transfected with anti-CD19 CAR pSBbiRP were 
incubated with biotinylated anti-c-myc mAb and detected with Brilliant Violet 421-conjugated 
streptavidin. Controls for both cell populations are shown stained with Brilliant Violet 421-
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Figure 13. Screening of serum for binding to FMC63 scFv based CAR. 
 Serum sourced from FMC63-huFc immunised mice was incubated with the Jurkat T cell line 
expressing the anti-CD19 CAR, or with untransfected Jurkat used as a control. Murine mAb was 
detected with the secondary antibody GAM IgG AF488, and expression of the RFP reporter 
gene present within the pSBbiRP plasmid was used to identify the transfected Jurkat cell 
population. Untransfected Jurkat cells only, Jurkat:CAR cells only, or a 1:1 ratio of 
untransfected Jurkat and Jurkat:CAR cells were either unstained (A, B, and C respectively), 
stained with secondary antibody GAM IgG AF488 alone (D, E, and F respectively), stained with 
a 1/3000 dilution of naïve BALB/c serum and detected with GAM IgG AF488 (G, H, and I 
respectively). Alternatively, untransfected Jurkat, Jurkat:CAR, and a 1:1 ratio of both were 
incubated with 1/3000 dilution of anti-FMC63 positive control serum from mouse A and 









































































































































































































































































































































































































































































































Figure 15. Confirmation of fluorescein conjugation of mAb. 
Fluorescein-conjugated hybridoma mAb were incubated with anti-mouse Ig beads, or negative 
control beads. The results are shown for the screen of all five mAb hybridoma clones; (A) A11.B1, 
(B) A2.D11, (C) D4.G6, (D) C6.G1, (E) D1.E7. 
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3.10 Generation of alterative antigen to generate increased affinity antibody 
The lack of isotype switching shown in the isotype ELISA results likely indicate that the B cells 
secreting FMC63 scFv specific mAb received sub-optimal T cell help during the development of 
the humoral immune response. Therefore, an alternative immunisation strategy was designed to 
elicit additional T cell help in future immunisations. Two tetanus toxoid peptide sequences, 
containing known T helper cell epitopes, were added to the c-terminus of Fc region of the FMC63-
huFc fusion protein83-85. To facilitate processing of these peptide sequences in antigen presenting 
cells, a cathepsin B cleavage site (GFLG) was included between the two TT epitopes. The 
FMC63-huFc gene was amplified via PCR and annealed with the geneblock DNA through 
sequence homology in the CH3 domain (Figure 16A). The annealed gene was then amplified with 
the FMC63 forward and TT2 reverse primers. The amplified PCR product was gel 
electrophoresed alongside the original FMC63-huFc without TT2 as a control (Figure 16 B). This 
showed a small shift in size as expected from the addition of the 122 bp geneblock. 
The PCR product and FMC-huFc backbone were restriction digested with NotI and HindIII before 
being ligated together. Ligated plasmid DNA was transformed into E.coli TOP10 and colony PCR 
performed to identify colonies harboring the vector of interest. It was shown that of ten total 
colonies screened, seven showed amplification at the correct band size ~1.6 kb (Figure 16C). 
Plasmid DNA was purified from colonies 4,6 and 7 and sent for sequencing. The results indicated 
that all three plasmids containing the FMC63-huFc gene with the addition of the two tetanus 
toxoid peptides (data not shown). Due to time constraints of this project no further tests, such as 




Figure 16. Overview and cloning of tetanus toxoid 2 (TT2) containing antigen. 
(A) Overview of geneblock containing p2 and p30 tetanus toxoid epitopes. CH3 represents a 
region of overlap between geneblocks and CH3 domain of human Fc.  
(B) Gel electrophoresis image of cloning of TT2 geneblock to FMC63-huFc gene. Lane 1, DNA 
ladder; Lane 2, milliQ control; Lane 3, FMC63-huFc; Lane 4, FMC63-huFc cloned with TT2 
geneblock. 
(C) Colony PCR of TOP10 E. coli colonies transfected with FMC63-huFc TT2 pcDNA3.1(-) 
plasmid. Lane 1 DNA ladder; Lanes 3-12 Top10 E. coli colonies transfected with FMC63-huFc 









The development of CAR T cell therapy has signalled a major breakthrough for the treatment of 
relapsed and refractory B cell malignancies. While the therapeutic outcomes have been 
impressive, there remains a significant lack of effective quality control reagents during therapy 
manufacture.86 As can be expected with biological therapies, variability is unavoidable; however, 
with appropriate reagents it may be possible to minimise or control this variability. While 
advances in factors such as intercellular signalling domains have driven drastic improvements in 
CAR T cell function, the single most important factor that dictates anti-tumour efficacy is CAR 
surface expression.47  
Current methods for detecting CAR expression rely on measures of gene expression or targeting 
of elements not present in clinically relevant CAR constructs (e.g. c-myc tag).86, 87 Gene 
expression-based methods may not provide an accurate representation of true CAR expression, 
with results typically overestimating the true level of expression.64 Additionally, the elements that 
can be readily targeted are useful for laboratory testing of CAR T cell but lack clinical 
applicability due to potential immunogenicity of antibody tag sequences. 
The ideal reagent for detection of anti-CD19 CAR expression is an anti-idiotype antibody 
recognising the FMC63-derived antigen recognition domain. One such reagent has been 
previously described (clone 136.20.1) by Jena and colleagues.66 Unfortunately, this reagent is no 
longer widely available. This project aimed to generate another such reagent through 
immunisation of mice with FMC63 scFv antigen and subsequent generation and screening of mAb 
secreting hybridomas. A mAb capable of binding to the scFv could potentially be used to assess 
surface CAR expression at a variety of stages throughout manufacture. Additionally, this reagent 
would provide a direct method for detecting CAR T cell persistence within patient’s blood, widely 
regarded as a surrogate measure for therapy efficacy.65 
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In order to induce an anti-FMC63 scFv immune response, soluble antigen containing the scFv 
was generated. Molecular cloning was performed to ligate the gene encoding the FMC63 scFv to 
IgG1 Fc constant region genes of both human and murine origin. The addition of Fc domains is 
widely utilised to allow for improvements in both the solubility and stability of N-terminal 
domains. 
The decision to use both human and murine Fc domains was based on their relative 
immunogenicity. The FMC63 scFv is derived from a murine antibody and therefore shares 
significant sequence similarity to other murine antibodies. It has been shown that to induce a 
significant immune response when immunising mice with self-antigen it is necessary for linked, 
foreign peptides to be present.88 The use of human Fc aimed to introduce foreign peptides to 
maximise reactivity generated against the FMC63 scFv region, effectively a self-antigen, as well 
as contributing useful properties of human Fc for solubility and purification. On the other hand, 
murine Fc is a self-protein and thus reactivity generated from this antigen should be directed only 
against the antigenic regions of the FMC63 scFv. The use of human Fc fusion protein to 
effectively initiate an immune response, and then subsequent immunisations with murine Fc 
fusion protein would provide the greatest likelihood of generating an FMC63 scFv specific 
response. 
The nature of the respective vector backbones allowed a single step ligation of the FMC63 scFv 
gene directly to the huFc backbone. This was not possible for cloning of FMC-muFc fusion 
protein, with ligation of three DNA fragments necessary. Multiple fragment ligations are typically 
less efficient than those with only two fragments.89 This is in agreement with our observations 
during this study, with unsuccessful ligation of the three fragments to generate FMC63-muFc 
(Figure 3D). 
Splicing by overlap extension (SOE) PCR was used to produce fusions of the FMC63 variable 
regions with the muFc domains. This method utilises a region of a shared junction sequence 
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between two adjacent primers, that allows genetic splicing through PCR amplification.90 Primers 
were designed to introduce a 30 bp region of homology in the linker region between FMC63 scFv 
and muFc genes. The amplification and subsequent ligation of the FMC63 scFv and muFc genes 
was successful, allowing for direct ligation of the gene insert to the digested vector backbone 
(Figure 4B). 
In order to immunise mice with FMC63 scFv antigen it was necessary to both express and purify 
the fusion protein. This was achieved through cationic lipid-mediated transfection of purified 
plasmid DNA into the planktonic HEK293-derived cell line, Expi293F. This cell line, along with 
other HEK293 derivatives, are widely utilised for the expression of recombinant proteins.91 The 
purification of FMC63-huFc fusion protein was successful with both protein A and G. However, 
FMC63-muFc was not readily purified (Figure 5). 
Protein A is known to bind effectively to human IgG1 Fc while having a relatively low affinity 
for murine IgG1 Fc.92 Protein G has a broader binding spectrum, including being able to bind both 
human and murine IgG1 Fc.92 While literature suggests that FMC63-muFc fusion protein should 
have been purified effectively with protein G, this did not correspond with our results with little 
to no FMC63-muFc eluted. Cell supernatant of Expi293F cultures transfected with the plasmid 
encoding the FMC63-muFc fusion protein was therefore screened via indirect ELISA to confirm 
the presence or absence of the fusion protein. Interestingly, results indicated that the FMC63-
muFc protein was successfully expressed, however the fusion protein was unable to be purified 
by the protein G column (Figure 5D). 
Purified fusion proteins containing non-scFv antigen produced in parallel showed a 10-fold 
increased yield compared to FMC63 scFv fusion proteins (unpublished data, McLellan lab). 
Additionally, non-scFv fusion proteins containing muFc were readily purified (unpublished data, 
McLellan lab). This indicates that the FMC63 scFv was interfering with the ability of fusion 
proteins to be purified via protein A or G columns, particularly murine Fc. It has been shown, 
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particularly in bacterial expression systems, that the correct folding of scFv is a delicate process. 
This is thought to be related to a variety of factors including the presence of solvent exposed 
hydrophobic residues and the length of the flexible linker between the VH and VL domains.38, 93 It 
is possible that these, or other, factors had an impact on the folding of the FMC63 scFv that 
negatively affected the purification of the fusion protein via protein A or G columns. 
It has been shown that the folding properties of scFv are easily altered, with small changes to 
factors such as amino acid sequence leading to drastic changes in solubility, or other functional 
properties.93 Additionally, the expression system utilised can have major implications for the 
correct folding of scFv.38 As FMC63 scFv is derived from a murine antibody it is possible that 
the use of the Expi293F expression system, based on a human cell line, may have altered the 
folding of the FMC63 scFv in a manner that lead to a lack of purification. The use of an alternative 
cell line, such as the Chinese hamster ovary cell line, may have presented an alternative to allow 
for correct folding as it represents a host organism more closely related to a murine cell. 
In order to provide a secondary FMC63 scFv antigen, HEK293 cells expressing the CD19 CAR 
construct were generated. This allowed for the FMC63 scFv to be presented in an intact CAR 
format, in addition to the Fc fusion protein format. Studies comparing the crystal structures of 
scFv in the context of Fc fusion proteins and CAR constructs are lacking, however, the use of 
intact CAR removed any possibility that the protein structure may have differed between the two 
antigens.  
The transfection of cells with the sleeping beauty plasmid was assessed through fluorescence 
microscopy and an RFP reporter gene. This indicated that transfections were high efficiency based 
upon the widespread RFP expression (Figure 6). However, this measure did not assess the 
expression of CAR on the cell surface. The HEK293 cell line represents a reliable vehicle for the 
expression of cell membrane proteins and have been used for applications such as screening of 
phage libraries, in which cell surface protein expression is absolutely crucial.94 Additionally, the 
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anti-CD19 CAR construct has been shown to expressed on the surface of transduced T cells within 
this McLellan laboratory (Figure 12). However, this surface CAR expression appeared sub-
optimal as determined by c-myc tag labelling. This may have meant that only a subset of 
HEK293:CAR were expressing surface CAR despite being RFP positive. This may have limited 
the amount of FMC63 scFv the transfected cells presented to immunised mice.  
The fusion protein antigen used to immunise mice contained two major determinants capable of 
inducing an immune response in mice, the FMC63 scFv and human Fc regions. As well as 
screening against the FMC63 scFv fusion protein, CR1-huFc was also used to assess serum 
reactivity generated against the human Fc region as a control. The results showed that the 
reactivity to human Fc was considerably greater than that observed against the FMC63 scFv 
specifically, indicating this region of antigen was the more immunogenic of the two (Figure 7). 
The majority of FMC63 scFv sequence will be recognised as self-antigen in an immunised mouse 
and therefore is subject to immune tolerance usually employed to avoid reactivity to self-
proteins.95, 96 B cells recognising self-antigen are typically removed from the immune system via 
mechanisms of both central and peripheral tolerance.96 As a result, the majority of B cells capable 
of recognising the FMC63 scFv, particularly those recognising murine framework regions, may 
have been inactivated or suppressed via mechanisms of peripheral tolerance. Those capable of 
recognising the idiotopes within the scFv may have avoided this tolerance and therefore 
represented the reactivity that was observed via ELISA. On the other hand, human Fc is not a self-
antigen and is therefore not subjected to the same tolerance mechanisms. Therefore, human Fc-
specific B cells will not have undergone tolerance measures and likely predominated in the 
immune response following immunisation. 
A similar phenomenon likely led to the lack of serum reactivity seen from mice immunised with 
HEK293:CAR cells. A similar whole cell immunisation protocol was utilised by Jena and 
colleagues to generate 136.20.1.66 This group utilised an allogeneic murine cell line to express 
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FMC63 scFv on the cell surface, while our work utilised a human cell line to immunise mice. The 
allogeneic L-cell line utilised in the Jena et al. study may provide T cell help via allogeneic  
MHC-II-peptide: TCR interactions.66 In our study, the use of a human cell line should have 
introduced a number of potentially highly antigenic determinants recognised by murine B cells. 
This may have led to immunodominance, where an immune response is directed against only a 
select few peptides despite a variety being present.97 The self versus non-self-nature of FMC63 
scFv- and HEK293-derived peptides respectively, likely meant that the immune response was 
skewed towards immunodominant HEK293 peptides. Previous studies immunising mice with 
human cell lines have generated varieties of antibodies specific for cell-derived glycoproteins, 
indicating that reactivity to cell-derived peptides can influence the immune response.98, 99 Studies 
have also utilised HEK293 whole cell immunisation methods for production of mAb against 
native viral proteins, however, the surface antigens utilised are foreign and therefore considerably 
more antigenic than FMC63 scFv.100 
It has previously been shown that to induce meaningful activity against self-antigen it is necessary 
to deliver protein with an adjuvant to break tolerance.88 This was lacking with HEK293:CAR 
immunisation, with cells administered in the presence of only PBS. Fusion protein immunisation 
was administered with two forms of Freund’s adjuvant, likely allowing for a break of tolerance 
resulting in the small FMC63 scFv specific immune response observed. 
Having observed no FMC63 scFv specific immune response, the mice previously immunised with 
HEK293:CAR were immunised with FMC63-huFc. Intriguingly, the serum antibody reactivity 
was considerably higher for CR1-huFc, the huFc control protein, than the immunising  
FMC63-huFc protein (Figure 8). These mice were immunised in parallel with mice that received 
IP injections of CR1-huFc antigen. However unlikely, it is impossible to rule out that human error 
by those administering the antigen resulted in the immunisation of mice with incorrect antigen 
and thus an immune response was generated against the CR1 antigen. CR1 is a key protein 
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involved in the maintenance of the undifferentiated state of embryonic and cancer stem cells.101 
Due to the origin of HEK293 being embryonic cells, it is possible that CR1 may be present in 
these cells; gene expression has been shown in human stem cell lines102, 103. However, flow 
cytometry screening of serum from CR1-immunised mice indicated no binding to HEK293 cells, 
indicating that a surface expressed CR1 on HEK293 was unlikely to have caused this reactivity 
(data not shown). 
Following immunisation, mice were sacrificed and hybridomas generated through the fusion of 
splenocytes with the non-secretory mouse myeloma cell line, NS/0. When hybridomas had 
undergone sufficient selection and cellular growth, screening was performed to identify those that 
had formed single colonies. Cell supernatant was screened via indirect ELISA as with serum, 
allowing for mAb binding to human Fc or FMC63 scFv to be differentiated. The vast majority of 
single colonies secreted mAb specific for the huFc region of the fusion protein antigen, in line 
with serum ELISA results (Figure 9). A total of 14 hybridomas secreting FMC63 scFv specific 
mAb were identified, representing 3.8% of all colonies screened (Figure 9). This is in line with 
other studies utilising hybridoma technology, with percentages of positive colonies ranging from 
roughly 2-5%.104, 105  
Mice that showed increased reactivity to CR1-huFc as compared to FMC63-huFc also produced 
hybridomas that appeared to secrete mAb specific for CR1. This further indicated exposure to 
CR1 antigen at some point throughout the immunisation schedule. The fourteen FMC63 scFv 
specific hybridomas, along with eleven CR1 specific clones, were re-cloned to ensure 
monoclonality. At this stage only five hybridomas were able to re-form single colonies. This 
removed the possibility of characterising the CR1 specific mAb that were being secreted, as well 
as nine of the FMC63 scFv specific mAb. The loss of such a significant number of hybridomas is 
not surprising due to the typical instability of hybridomas coupled with variable size of single 
colonies upon re-cloning.  
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As previously mentioned, the expression of anti-CD19 CAR on the surface of Jurkat T cells used 
in this study was 24.6% (Figure 12). This value is lower than other published studies that have 
utilised c-myc tags for assessing the levels of surface CAR expression.86, 106 Despite fairly modest 
CAR expression, this level of expression is sufficient for these cells to have desired effector 
function as assessed via an IL-2 release assay (unpublished data, McLellan lab). Therefore, these 
cells were a suitable model of CAR T cells capable of responding to target antigen binding. The 
desired antibody to bind CAR constructs would be high affinity for a particular FMC63 scFv 
derived epitope to allow for binding to constructs that are expressed in only a subset of transduced 
T cells. 
The mAb purified from hybridoma supernatant showed ability to bind FMC63 scFv via ELISA, 
however, were unable to detect the surface expression of FMC63 scFv in the context of the anti-
CD19 CAR. Intriguingly, the whole serum from an immunised mouse showed that mAb capable 
of binding to CD19 CAR via flow cytometry were generated (Figure 13). This indicated that 
although these mAb were not isolated from immunised mice via hybridoma generation, the 
immunisation schedule did result in production of plasma cells secreting anti-FMC63 mAb 
capable of binding FMC63 scFv the context of a CAR.  
Isotype analysis of mAb showed that four of five FMC63 scFv specific hybridomas were of IgM 
isotype (Figure 11). This indicated that these mAb had not undergone isotype switching during 
the immune response following immunisation. Isotype switching is a process in which the genes 
encoding the constant domains of an antibody are differentially spliced to generate constant 
domains with varying effector functions.107 This is a process that plays an important role in the 
effective functioning of the humoral immune response following recognition of pathgoens.108 IgM 
represents the early isotype present on naïve B cells prior to class switch induction. The process 
of class switching is initiated upon antigen recognition and co-stimulation by T cells specific for 
peptides presented by B cells on MHC-II.107 Co-stimulation from helper T cells is also known to 
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control the entry of B cells to germinal centers following recognition of native antigen, where 
somatic alterations to B cell receptor affinity occur via somatic hypermutation.109 The results 
indicate that the B cells that generated FMC63 scFv specific hybridomas did not undergo these 
affinity increasing rearrangements induced by T cell help. 
T cell help provides not only signals for class switching, but also drives somatic hypermutation 
of variable regions in both the heavy and light chains.110 Therefore, IgM represents an antibody 
isotype that is normally associated with low affinity antibodies, but IgM antibodies may possess 
acceptable avidity through their pentameric structure. The density of FMC63 scFv was likely 
considerably higher in the ELISA which utilised plate-bound fusion protein, compared to surface 
expressed CAR on Jurkat:CAR T cells. This may have allowed for multiple antigen binding sites 
of the pentameric IgM to bind multiple FMC63 scFv epitopes during ELISA, while the affinity 
of the antibody was not sufficient to bind low density single FMC63 scFv present on the 
Jurkat:CAR cells. 
Alternatively, the FMC63-huFc fusion protein was shown to dimerise, a common feature of IgG1 
Fc fusion proteins (Figure 5C).111 It is possible that the antibodies generated may have recognised 
epitopes present only when the protein was in a dimerised form. These epitopes from dimerised 
FMC63 scFv fusion protein will likely have been recapitulated in the Fc fusion protein ELISA, 
however, will not have been present with surface expressed CAR constructs.  
The FMC63-huFc fusion protein contained a flexible linker between the FMC and Fc domains. 
The same was true for the CD19 CAR construct used in this screening, however, the two linkers 
differed significantly. The CD19 CAR construct contains a hinge derived from human CD8, while 
this is not present in the FMC63-huFc fusion protein. Therefore, the two linkers differed between 
ELISA and flow cytometry screens and it is possible that the mAb observed to bind to FMC63 
scFv during ELISA screening were in fact binding the flexible linker. Such as antibody would not 
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be desirable for CAR T cell therapy as it would remove the ability to detect CD19 CAR constructs 
that did not contain a particular linker type. 
Immunisation of mice with self-antigens with the aim to generate high-affinity, class-switched 
mAb is difficult due to the need to overcome immune tolerance in the host organisms. The 
introduction of additional T cell epitopes in this project aimed to generate increased T cell help in 
future immunisations with FMC63-huFc protein. A method that has been utilised previously is 
the addition of elements containing known T cell epitopes to immunising antigens.83 Two such 
elements are the p2 and p30 peptides derived from the tetanus toxin.83 These two epitopes were 
grafted onto C-terminus of the Fc domain of FMC63-huFc gene (Figure 16B, 16C). The chosen 
T cell epitopes, p2 and p30, have been shown previously to lead to high specificity IgG serum 
reactivity following immunisation with a mouse self-antigen.83 The increase in T cell help will 
likely lead to higher-affinity, class switched antibodies being generated. While the human Fc 
domain of the fusion protein will likely still generate the majority of reactivity, B cells producing 
FMC63 scFv specific mAb will be more likely to undergo affinity maturation in the GC reaction. 
This will increase the likelihood of FMC63 scFv specific mAb possessing the required affinity to 
bind the low density FMC63 scFv presented on CAR constructs. 
4.2 Future work 
This work identified that it is possible to generate FMC63 scFv specific mAb with Fc fusion 
protein immunisation of mice. The mAb generated did not undergo class switching indicating that 
a lack of T cell help was generated for these B cells. Future immunisations of mice with FMC63 
scFv will utilise the newly generated construct containing tetanus T cell epitopes. This will ideally 
lead to higher affinity antibody generation, with an increased likelihood of mAb being able to 
bind low density FMC63 scFv. 
Screening of whole serum of immunised mice against CAR expressing Jurkat cells indicated that 
there were mAb generated that were capable of binding surface expressed CD19 CAR. 
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Unfortunately, none of these FMC63 CAR-specific plasma cells successfully fused to create a 
hybridoma cell. The nature of hybridoma technology means that only a fraction of plasma cells 
are able to generate hybridomas, with effectively 369 B cells from four immunised mice screened 
in this project. Therefore, only a fraction of potential antibodies generated are made available for 
screening. A higher throughput method, such a phage display, would allow for a substantial 
increase in the amount of potential mAb screened. This method would allow for the screening of 
effectively all mAb generated during an immune response and therefore increase the likelihood 




In this research, antigens capable of inducing an anti-FMC63 scFv immune response were 
generated. The antigens were used to immunise mice and generate mAb secreting hybridoma 
cells. A total of fourteen FMC63 scFv specific mAb were identified that bound purified FMC63 
scFv fusion protein. Unfortunately, these mAb were unable to have the same effect when screened 
for their ability to bind surface expressed CAR. Isotype analysis indicated that the B cells did not 
receive sufficient T cell help necessary to undergo class switching and processes in which affinity 
is improved. As a result, a new construct was generated to induce improved T cell help within 
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